Overview
The primary objective of this study is to compare total narcotic intake standardized via milligram morphine equivalents between duloxetine and placebo cohorts after a total hip arthroplasty.
Eligibility
Inclusion Criteria:
- Patients > 18 years of age
- Patients undergoing primary total hip arthroplasty
- Ambulatory patient prior to fracture
- Subjects must be capable of providing informed consent
- English or Spanish speaking
Exclusion Criteria:
- Previous hemiarthroplasty or THA on ipsilateral hip
- History of Complex Regional Pain Syndrome in ipsilateral extremity
- History of demyelinating disorder or neurologic deficit that may contribute to altered pain tolerance or sensation
- Acute or chronic hip infection in ipsilateral extremity
- Pregnant or breastfeeding
- Open fracture
- Polytrauma
- Intravenous or drug users within 6 months of surgery
- Liver Failure via clinical diagnosis or international normalized ratio greater than 1.5 or partial thromboplastin time greater than 40
- Patients on selective serotonin reuptake inhibitor, serotonin norepinephrine reuptake inhibitor, monoamine oxidase inhibitor, and/or tricyclic anti-depressant
- Severe renal dysfunctions, such as glomerular filtration rate less than 30
- Moderate to severe depression as diagnosed by a clinician
- Taking cytochrome P450 1A2 inhibitors and cytochrome P450 1A6 inhibitors for the duration of 5 half-lives as these drugs are clinically eliminated within 5 half-lives
- History of uncontrolled narrow angle glaucoma